AQST today
$3.46-$0.12 (-3.35%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourDescending Triangle
15 minExpanding
5 minStrong Bearish
Daily trend turns up above $4.04
Key levels
Resistance$4.04
Resistance$3.63
Support$3.37
Support$2.93
Latest news & SEC filings
SEC FilingAquestive Therapeutics, Inc. filed an insider trading report (Form 4)
All AQST news →About Aquestive Therapeutics
Aquestive Therapeutics develops and manufactures medicines that use dissolvable oral film strips to deliver drugs. Its lead candidate, Anaphylm, is a sublingual epinephrine prodrug film for severe allergic reactions, supported by the AdrenaVerse epinephrine prodrug platform and the topical gel candidate AQST-108. The firm also produces licensed products for partners, including Suboxone for opioid dependence and Emylif for ALS, and developed Libervant, a buccal diazepam film for epilepsy seizure clusters. Manufacturing takes place in Indiana, while its headquarters and main research site are in New Jersey.
Based on the company's 10-K filed Mar 4, 2026.
Nasdaq · Healthcare
Aquestive Therapeutics, Inc. (AQST)
What Is the Price Target for AQST?
SEPT Low Target
$10.00
SEPT Mid Target
$10.00
SEPT High Target
$10.00
Analyst Consensus
$10.00
Is AQST a Buy or Sell Right Now?
Thesis
- •Revenue growing -22.6% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AQST.
Start Free Trial →Is AQST Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$10.00
17
Moat Score
NONE
2/9
Piotroski Score
-3.0
Altman Z-Score
What Is Smart Money Doing with AQST?
Insider Signal
SELLING
0 buys / 10 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Cochran John | director | Buy | 62,229 | - | Oct 21, 2026 |
| Barber Daniel | director officer | Sale | 25,000 | $106K | Oct 15, 2026 |
| Korczynski Sherry | officer | Buy | 8,750 | $23K | Sep 9, 2026 |
| Korczynski Sherry | officer | Sale | 8,750 | $46K | Sep 9, 2026 |
| Korczynski Sherry | officer | Sale | 2,714 | - | Jun 8, 2026 |
| Zalewski Thomas A. | officer | Buy | 100,000 | - | May 18, 2026 |
| Barber Daniel | officer | Sale | 8,257 | $35K | May 15, 2026 |
| Cioffi Melina | officer | Sale | 1,667 | $7K | May 15, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AQST Growth Story
Revenue YoY
-22.6%
3yr Revenue CAGR
-2.2%
EPS Growth YoY
-52.94%
FCF Growth YoY
-47.5%
Revenue Trend
DECLINING
Dark Pool Trades for AQST
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AQST, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 15:22:25 | $3.46 | 1,300 | $$5K | BUY |
| 15:20:20 | $3.46 | 5,000 | $$17K | BUY |
| 15:20:12 | $3.45 | 5,000 | $$17K | SELL |
| 15:19:55 | $3.46 | 4,000 | $$14K | MIDPOINT |
| 15:19:46 | $3.46 | 1,400 | $$5K | BUY |
5 dark pool trades shown · $$58K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Aquestive Therapeutics, Inc. (AQST) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AQST — frequently asked questions
What is AQST stock price today?
Aquestive Therapeutics, Inc. (AQST) is at $3.46, down 3.35% (-$0.12) at the Nov 12, 2026 close.
Why is AQST stock moving today?
Latest AQST news — Nov 10, 2026: Aquestive Therapeutics, Inc. filed an insider trading report (Form 4)
What is the AQST price target?
The average analyst price target for AQST is $10.00, ranging from $10 to $10, based on 1 analysts.
What do analysts rate AQST?
Analyst ratings for AQST: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did AQST beat earnings?
AQST last reported on Aug 11, 2026: EPS -$0.18 vs -$0.10 expected — a miss of 71.4%.
Does AQST pay a dividend?
AQST does not currently pay a dividend.
How much debt does AQST have?
Aquestive Therapeutics, Inc. reported $51M of debt and $98M of cash (Jun 30, 2026).
What are AQST support and resistance levels?
Support: $3.37, $2.93, $2.59. Resistance: $3.63, $4.04, $4.29.
What are insiders doing with AQST?
Insider activity: SELLING, 0 buys and 10 sells in the last 90 days.
What is the latest news on AQST?
Nov 10, 2026: Aquestive Therapeutics, Inc. filed an insider trading report (Form 4)